Adrenomedullin research: AM1 and AM2 receptor assembly, signaling, kinetics, and assay design

1) Define both the ligand and the receptor complex

Mature human adrenomedullin (ADM or AM) contains 52 amino acids, an intramolecular disulfide bond between Cys16 and Cys21, and an amidated Tyr52. Those features are not cosmetic identifiers. The disulfide-constrained N-terminal region contributes to activation, while the amidated C-terminal region engages the extracellular receptor domain. Reduced, mispaired, truncated, or non-amidated material should not be assumed to reproduce the activity of intact AM(1–52).

The receptor is not CLR alone. Calcitonin receptor-like receptor, encoded by CALCRL, requires a receptor activity-modifying protein for efficient surface delivery and ligand phenotype. CLR with RAMP2 forms the AM1 receptor; CLR with RAMP3 forms the AM2 receptor. CLR with RAMP1 instead produces the canonical CGRP receptor. Because the same GPCR core participates in all three complexes, measuring CALCRL without the relevant RAMP cannot identify the functional receptor population.

Adrenomedullin 2, also called intermedin, and CGRP can activate overlapping members of this receptor family depending on species, concentration, and assay context. Reagent records should therefore state exact sequence, species, amidation, disulfide status, peptide content, purity method, counterion, solvent, lot, vessel, and freeze–thaw history. Model records should include CLR and each RAMP at transcript, total-protein, and surface-complex levels.

2) RAMP2 and RAMP3 reshape one GPCR into distinct receptors

Cryo-EM structures captured AM-bound AM1 and AM2 receptors coupled to Gs, along with an adrenomedullin-2-bound AM2 receptor. They showed the class B GPCR pattern in which the peptide C terminus associates with the extracellular domain and the N-terminal portion enters the transmembrane core. RAMP2 and RAMP3 made extensive contacts with CLR, yet their extracellular-domain orientation, linker behavior, and influence on extracellular loop 3 differed. Particle-motion analysis suggested that extracellular-domain dynamics can be coordinated with G-protein orientation.^[1]

These structures provide a mechanistic framework, not a direct potency table for every model. The complexes used purified, engineered proteins and stabilizing conditions selected for structural capture. Validate any proposed contact with matched full-length receptors, surface-expression measurements, binding, and a proximal signaling assay. A mutation that reduces cAMP can impair folding, heterodimerization, surface delivery, ligand affinity, activation efficacy, or G-protein coupling.

A complementary mutagenesis study tested 68 CLR residues with RAMP2 and RAMP3. Sixteen substitutions produced different functional effects between the two receptor complexes. Modeling also predicted different pocket geometry and electrostatics, supporting an allosteric mechanism by which each RAMP changes the CLR juxtamembrane region.^[2] The key lesson for assay design is that RAMPs are active determinants of receptor conformation, not passive trafficking chaperones.

3) Separate Gs engagement from amplified downstream biology

AM1 and AM2 receptors canonically activate Gs and raise intracellular cAMP. A cAMP concentration-response curve is useful, but it combines receptor abundance, receptor reserve, G-protein coupling, adenylyl cyclase activity, phosphodiesterase activity, incubation time, and detector range. EC50 is therefore a system-dependent potency estimate, not binding affinity and not an intrinsic molecular constant.

Begin with a direct Gs activation or dissociation sensor where feasible, then pair it with kinetic cAMP measurement. Report baseline, maximal response, time to peak, sustained phase, and washout behavior. If forskolin or a phosphodiesterase inhibitor is used, document the concentration and verify that the detector remains within its linear range. For cross-system comparisons, match surface receptor abundance and retain raw response amplitudes alongside normalized curves.

ERK phosphorylation, calcium flux, barrier permeability, migration, proliferation, transcript abundance, or morphology can be biologically informative but sit downstream of multiple pathways. They cannot establish AM1 versus AM2 identity by themselves. Use loss-and-rescue experiments for CALCRL, RAMP2, or RAMP3, and establish the temporal sequence from receptor activation to phenotype. Pharmacological fragments may help, but imperfect family selectivity and receptor reserve make genetic confirmation important.

Receptor internalization and recycling should be measured independently of cAMP. Quantify surface CLR-RAMP complex, total receptor, and subcellular localization at defined times. Extracellular tags or complementation systems need controls showing that they preserve assembly, ligand pharmacology, Gs coupling, and trafficking. A reduction in surface signal does not distinguish internalization from epitope masking, shedding, or degradation.

4) Exposure time can change apparent ligand selectivity

Ligand-receptor residence time is an important experimental variable in this family. A primary kinetic study compared adrenomedullin with adrenomedullin 2/intermedin at CLR-RAMP receptors using cAMP time courses, antagonist challenge, washout, mutagenesis, and structural analysis. Adrenomedullin 2 behaved as a slow-off-rate, long-acting endogenous agonist at the AM2 receptor, and RAMP3 extracellular-domain contacts helped explain the persistent response.^[3]

That result illustrates why a single endpoint can mis-rank ligands. Two peptides may look similar during continuous exposure but separate after washout or competitive antagonist addition. Conversely, delayed reporter accumulation may exaggerate a transient upstream difference. For every new model, pilot association, washout, antagonist-challenge, and rechallenge windows before fixing the assay endpoint.

Distinguish continued signaling by surface receptors from signaling after internalization and from slow peptide clearance. Include ligand-free washout verified analytically, receptor-location measurements, and a membrane-impermeant antagonist where validated. Analyze full time courses or prespecified kinetic parameters rather than selecting the largest post hoc difference.

5) Peptide degradation changes the exposure mixture

An early metabolism study incubated human AM(1–52) with ovine adrenal, kidney, and lung plasma-membrane preparations. It identified AM(2–52) and AM(8–52) as major products, with smaller amounts of AM(26–52), AM(27–52), AM(28–52), and AM(33–52). EDTA and 1,10-phenanthroline inhibited degradation, supporting metalloprotease activity followed by aminopeptidase processing.^[4]

These products and rates must not be transferred directly to cell culture, plasma, organoids, tissue slices, or purified-receptor assays. Species, tissue source, membrane preparation, temperature, protein concentration, and peptidase repertoire all differ. Qualify intact AM and expected fragments under the actual matrix, vessel, concentration, and time course used. Include time-zero standards, matrix blanks, extraction-recovery controls, and a validated mass-resolved assay.

Immunoassays can be valuable for concentration screening, but antibody recognition does not prove correct disulfide pairing, terminal amidation, or intact sequence. LC-MS methods should evaluate recovery, matrix suppression, linearity, carryover, and fragment separation. If intact peptide declines during the biological window, interpret the result as exposure to a changing mixture rather than assigning the final phenotype exclusively to the starting material.

6) A reproducible adrenomedullin laboratory workflow

1. Specify the peptide. Record sequence, species, amidation, disulfide status, peptide content, counterion, purity, lot, concentration method, and handling history.
2. Qualify the receptor. Measure CLR, RAMP2, and RAMP3 transcripts, total proteins, surface complexes, and relevant endogenous CGRP-family components.
3. Validate exposure. Quantify intact AM and major fragments across the intended matrix, vessel, temperature, and assay duration.
4. Establish kinetics. Pilot Gs, cAMP, internalization, washout, antagonist challenge, and rechallenge before choosing endpoints.
5. Resolve receptor identity. Combine matched CLR-RAMP panels with subunit knockout and rescue; do not rely on one antagonist or transcript measurement.
6. Use orthogonal readouts. Pair proximal signaling with one downstream phenotype and measure surface receptor separately from total receptor.
7. Predefine analysis. State curve model, kinetic parameter, normalization, replicate hierarchy, exclusions, and statistical plan.

7) Evidence limits and common errors

• Do not call CLR alone an AM receptor. RAMP identity determines surface expression and receptor phenotype.
• Do not infer functional AM1 or AM2 receptor from RNA alone. Verify the assembled surface complex and proximal response.
• Do not equate cAMP EC50 with affinity. Amplification, receptor reserve, degradation, and timing shape the curve.
• Do not compare ligands at one arbitrary time point. Association and dissociation kinetics can reverse an apparent rank order.
• Do not interpret immunoreactivity as intact AM. Sequence integrity, amidation, and disulfide status require orthogonal analysis.
• Do not transfer ovine membrane-degradation kinetics to another matrix. Measure stability in the actual experimental system.
• Do not extrapolate structural, cellular, or animal findings into self-use, treatment, performance, or anti-aging claims. Conclusions remain limited to the tested model.

A rigorous adrenomedullin experiment links a chemically defined peptide to a verified CLR-RAMP complex, a proximal Gs event, a time-resolved receptor fate, and measured exposure integrity. That chain separates receptor pharmacology from accessory-protein abundance, reporter amplification, slow dissociation, and proteolytic conversion.